Shares of AstraZeneca Pharma India gained as much as 3 percent to Rs 6,890 in afternoon trade on March 3 after the company announced it has secured regulatory approval to expand the use of its cancer therapy, Imfinzi, in the country.
The Central Drugs Standard Control Organisation (CDSCO) has granted the company permission to import, sell, and distribute Durvalumab (Imfinzi) for an additional indication—treating patients with unresectable hepatocellular carcinoma (uHCC), a form of liver cancer.
This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients battling advanced-stage liver cancer. While the company still requires other statutory approvals before launching the expanded indication in India, the regulatory green light marks a crucial step in AstraZeneca Pharma’s oncology portfolio expansion.
AstraZeneca Pharma India delivered a stellar performance in Q3FY25, with net profit surging 94.9 percent year-on-year to Rs 30.8 crore, up from Rs 15.8 crore in the same period last year.
